Search

Your search keyword '"Kuramatsu, Joji B"' showing total 6 results
Start Over Author "Kuramatsu, Joji B" Journal annals of neurology
6 results on '"Kuramatsu, Joji B"'

1. Association of prothrombin complex concentrate administration and hematoma enlargement in non–vitamin K antagonist oral anticoagulant–related intracerebral hemorrhage

Author

Gerner, Stefan T., Kuramatsu, Joji B., Sembill, Jochen A., Sprügel, Maximilian I., Endres, Matthias, Haeusler, Karl Georg, Vajkoczy, Peter, Ringleb, Peter A., Purrucker, Jan, Rizos, Timolaos, Erbguth, Frank, Schellinger, Peter D., Fink, Gereon R., Stetefeld, Henning, Schneider, Hauke, Neugebauer, Hermann, Röther, Joachim, Claßen, Joseph, Michalski, Dominik, Dörfler, Arnd, Schwab, Stefan, Huttner, Hagen B., Horn, Markus, Bahner, Dirk, Hagemann, Georg, Rakers, Florian, Endres, Matthias, Haeusler, Karl Georg, Sobesky, Jan, Schurig, Johannes, Zweynert, Sarah, Bauer, Miriam, Vajkoczy, Peter, Fink, Gereon R., Dohmen, Christian, Stetefeld, Henning, Schwarz, Michael, Reimann, Gernot, Reichmann, Heinz, Schneider, Hauke, Rahmig, Jan, Gerner, Stefan T., Kuramatsu, Joji B., Bogenreuther, Christina, Sembill, Jochen A., Sprügel, Maximilian I., Hagen, Manuel, Knappe, Ruben, Köhrmann, Martin, Schwab, Stefan, Huttner, Hagen B., Kloska, Stephan P., Dörfler, Arnd, Ringwald, Jürgen, Hamann, Gerhard F., Röther, Joachim, Michels, Peter, Ringleb, Peter A., Purrucker, Jan, Rizos, Timolaos, Witte, Otto W., Günther, Albrecht, Wöhrle, Johannes C., Alshammari, Fahid, Claßen, Joseph, Michalski, Dominik, Grau, Armin, Palm, Frederick, Urbanek, Christian, Schellinger, Peter D., Glahn, Jörg, Knappe, Ulrich J., Wiendl, Heinz, Fisse, Anna Lena, Minnerup, Jens, Erbguth, Frank, Nueckel, Martin, Bäzner, Hansjörg, Schwert, Henning, Ludolph, Albert Christian, Stösser, Sebastian, Neugebauer, Hermann, Volkmann, Jens, Müllges, Wolfgang, Kraft, Peter, and Schubert, Anna‐Lena

Published
2018
Full Text
View/download PDF

2. Oral Anticoagulation and Functional Outcome after Intracerebral Hemorrhage

Author

Biffi, Alessandro, Kuramatsu, Joji B., Leasure, Audrey, Kamel, Hooman, Kourkoulis, Christina, Schwab, Kristin, Ayres, Alison M., Elm, Jordan, Gurol, M. Edip, Greenberg, Steven M., Viswanathan, Anand, Anderson, Christopher D., Schwab, Stefan, Rosand, Jonathan, Testai, Fernando D., Woo, Daniel, Huttner, Hagen B., and Sheth, Kevin N

Published
2017
Full Text
View/download PDF

4. Multicenter Validation of the max‐ICH Score in Intracerebral Hemorrhage

Author

Sembill, Jochen A., primary, Castello, Juan P., additional, Sprügel, Maximilian I., additional, Gerner, Stefan T., additional, Hoelter, Philip, additional, Lücking, Hannes, additional, Doerfler, Arnd, additional, Schwab, Stefan, additional, Huttner, Hagen B., additional, Biffi, Alessandro, additional, and Kuramatsu, Joji B., additional

Published
2020
Full Text
View/download PDF

5. Multicenter Validation of the max‐ICH Score in Intracerebral Hemorrhage.

Author

Sembill, Jochen A., Castello, Juan P., Sprügel, Maximilian I., Gerner, Stefan T., Hoelter, Philip, Lücking, Hannes, Doerfler, Arnd, Schwab, Stefan, Huttner, Hagen B., Biffi, Alessandro, and Kuramatsu, Joji B.

Subjects
CEREBRAL hemorrhage, DECISION making, LONGITUDINAL method
Abstract

Objective: Outcome prognostication unbiased by early care limitations (ECL) is essential for guiding treatment in patients presenting with intracerebral hemorrhage (ICH). The aim of this study was to determine whether the max‐ICH (maximally treated ICH) Score provides improved and clinically useful prognostic estimation of functional long‐term outcomes after ICH. Methods: This multicenter validation study compared the prognostication of the max‐ICH Score versus the ICH Score regarding diagnostic accuracy (discrimination and calibration) and clinical utility using decision curve analysis. We performed a joint investigation of individual participant data of consecutive spontaneous ICH patients (n = 4,677) from 2 retrospective German‐wide studies (RETRACE I + II; anticoagulation‐associated ICH only) conducted at 22 participating centers, one German prospective single‐center study (UKER‐ICH; nonanticoagulation‐associated ICH only), and 1 US‐based prospective longitudinal single‐center study (MGH; both anticoagulation‐ and nonanticoagulation‐associated ICH), treated between January 2006 and December 2015. Results: Of 4,677 included ICH patients, 1,017 (21.7%) were affected by ECL (German cohort: 15.6% [440 of 2,377]; MGH: 31.0% [577 of 1,283]). Validation of long‐term functional outcome prognostication by the max‐ICH Score provided good and superior discrimination in patients without ECL compared with the ICH Score (area under the receiver operating curve [AUROC], German cohort: 0.81 [0.78–0.83] vs 0.74 [0.72–0.77], p < 0.01; MGH: 0.85 [0.81–0.89] vs 0.78 [0.74–0.82], p < 0.01), and for the entire cohort (AUROC, German cohort: 0.84 [0.82–0.86] vs 0.80 [0.77–0.82], p < 0.01; MGH: 0.83 [0.81–0.85] vs 0.77 [0.75–0.79], p < 0.01). Both scores showed no evidence of poor calibration. The clinical utility investigated by decision curve analysis showed, at high threshold probabilities (0.8, aiming to avoid false‐positive poor outcome attribution), that the max‐ICH Score provided a clinical net benefit compared with the ICH Score (14.1 vs 2.1 net predicted poor outcomes per 100 patients). Interpretation: The max‐ICH Score provides valid and improved prognostication of functional outcome after ICH. The associated clinical net benefit in minimizing false poor outcome attribution might potentially prevent unwarranted care limitations in patients with ICH. ANN NEUROL 2021;89:474–484 [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

6. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage

Author

Gerner, Stefan T, Kuramatsu, Joji B, Erbguth, Frank, Schellinger, Peter D, Fink, Gereon R, Stetefeld, Henning, Schneider, Hauke, Neugebauer, Hermann, Röther, Joachim, Claßen, Joseph, Michalski, Dominik, Dörfler, Arnd, Sembill, Jochen A, Schwab, Stefan, Huttner, Hagen B, II, RETRACE, Horn, Markus, Bahner, Dirk, Hagemann, Georg, Rakers, Florian, Haeusler, Karl Georg, Sobesky, Jan, Schurig, Johannes, Sprügel, Maximilian I, Zweynert, Sarah, Bauer, Miriam, Vajkoczy, Peter, Dohmen, Christian, Schwarz, Michael, Reimann, Gernot, Reichmann, Heinz, Endres, Matthias, Bogenreuther, Christina, Hagen, Manuel, Knappe, Ruben, Köhrmann, Martin, Kloska, Stephan P, Ringwald, Jürgen, Hamann, Gerhard F, Michels, Peter, Ringleb, Peter A, Purrucker, Jan, Rizos, Timolaos, Witte, Otto W, Günther, Albrecht, Wöhrle, Johannes C, Alshammari, Fahid, Grau, Armin, Palm, Frederick, Urbanek, Christian, Glahn, Jörg, Knappe, Ulrich J, Wiendl, Heinz, Fisse, Anna Lena, Minnerup, Jens, Nueckel, Martin, Bäzner, Hansjörg, Schwert, Henning, Stösser, Sebastian, Volkmann, Jens, Müllges, Wolfgang, Kraft, Peter, Schubert, Anna-Lena, and Köhrmann, Martin (Beitragende*r)

Subjects
Male, therapeutic use [Hemostatics], Medizin, epidemiology [Germany], adverse effects [Blood Coagulation Factors], Blood Pressure, Hemostatics, therapeutic use [Blood Coagulation Factors], mortality [Hematoma], Cohort Studies, Germany, Humans, ddc:610, Hospital Mortality, adverse effects [Anticoagulants], Aged, Cerebral Hemorrhage, Retrospective Studies, Aged, 80 and over, prothrombin complex concentrates, Hematoma, pathology [Cerebral Hemorrhage], pathology [Hematoma], chemically induced [Cerebral Hemorrhage], chemically induced [Hematoma], Anticoagulants, Middle Aged, Blood Coagulation Factors, Treatment Outcome, Factor Xa, Female, mortality [Cerebral Hemorrhage]
Abstract

To investigate parameters associated with hematoma enlargement in non-vitamin K antagonist oral anticoagulant (NOAC)-related intracerebral hemorrhage (ICH).This retrospective cohort study includes individual patient data for 190 patients with NOAC-associated ICH over a 5-year period (2011-2015) at 19 departments of neurology across Germany. Primary outcome was the association of prothrombin complex concentrate (PCC) administration with hematoma enlargement. Subanalyses were calculated for blood pressure management and its association with the primary outcome. Secondary outcomes include associations with in-hospital mortality and functional outcome at 3 months assessed using the modified Rankin Scale.The study population for analysis of primary and secondary outcomes consisted of 146 NOAC-ICH patients with available follow-up imaging. Hematoma enlargement occurred in 49/146 (33.6%) patients with NOAC-related ICH. Parameters associated with hematoma enlargement were blood pressure ≥ 160mmHg within 4 hours and-in the case of factor Xa inhibitor ICH-anti-Xa levels on admission. PCC administration prior to follow-up imaging was not significantly associated with a reduced rate of hematoma enlargement either in overall NOAC-related ICH or in patients with factor Xa inhibitor intake (NOAC: risk ratio [RR] = 1.150, 95% confidence interval [CI] = 0.632-2.090; factor Xa inhibitor: RR = 1.057, 95% CI = 0.565-1.977), regardless of PCC dosage given or time interval until imaging or treatment. Systolic blood pressure levels 160mmHg within 4 hours after admission were significantly associated with a reduction in the proportion of patients with hematoma enlargement (RR = 0.598, 95% CI = 0.365-0.978). PCC administration had no effect on mortality and functional outcome either at discharge or at 3 months.In contrast to blood pressure control, PCC administration was not associated with a reduced rate of hematoma enlargement in NOAC-related ICH. Our findings support the need of further investigations exploring new hemostatic reversal strategies for patients with factor Xa inhibitor-related ICH. Ann Neurol 2018;83:186-196.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results